Home | Medical-Newswire.Com:
(EMAILWIRE.COM, March 21, 2012 ) New York, NY -- NovaBay Pharmaceuticals (NBY) released news this week that offers to broaden the scope and reach of the company's Aganocide compounds, which are being positioned as anti-infectives and could potentially replace modern day antibiotics as resistance to such treatment grows.
On Tuesday NovaBay announced a deal with Virbac Animal Health to bring its technology to the veterinary market. According to the agreement, NovaBay will receive an upfront payment - and some additional support for research and development - while Virbac will retain the option to license any of the Aganocide compounds that are successfully applied to treating veterinary indications.
The deal could provide NovaBay with a steady revenue stream in the future if Virbac exercises its licensing option. According to the Tuesday press release, if the option is exercised,
"NovaBay may receive additional payments, which include an exercise fee as well as development and pre-commercial milestones for a line of veterinary products. NovaBay will also receive royalties on sales of any successfully commercialized Aganocide products to arise from this agreement."
Few companies are going to become superpowers in the field of medicine on treating veterinary indications alone, but the deal brings some attention back to NovaBay and gives us another chance to consider this company's technology on the open market - should the pipeline products make it that far.
It also gives us the opportunity to determine whether or not the current market capitalization for NBY justifies that pipeline potential, which, in the opinion of this writer, the determination is "probably not."
First, let's revisit the problem of antibiotic resistance.
When introduced into society seventy years ago, antibiotics changed the shape of medicine, and provided what - at the time - was considered a huge leap forward in treating bacterial infections. Having been so widely-used since then, however, the infectious organisms against which the antibiotics are administered have grown increasingly resistant, and sometimes immune, to today's antibiotic treatments.
The Centers for Disease Control and Prevention considers the developing resistance to antibiotics as a "crisis", noting on its website that, "These drugs have been used so widely and for so long that the infectious organisms the antibiotics are designed to kill have adapted to them, making the drugs less effective. People infected with antimicrobial-resistant organisms are more likely to have longer, more expensive hospital stays, and may be more likely to die as a result of the infection."
Medical professionals themselves understand the growing risks associated with antibiotic resistance, as noted by Dr. Marc Siegel, associate professor of medicine and medical director of Doctor Radio at NYU Langone Medical Center, this week in an article published on FoxNews.com. Dr. Siegel also notes that Doctors continue to over prescribe these treatments, thereby strengthening the resistance of the surviving bacteria and creating new "super colonies" that will eventually be uncontrollable.
This dilemma has created a huge monetary burden on the global health care system and is possibly setting up a one-time "miracle cure" as irrelevant.
That's where NovaBay comes into the picture.
NovaBay has developed, through its proprietary Aganocide compounds, a pipeline of synthetic anti-infectives that are designed to mimic the body's own defenses against infection. Namely, these synthetic molecules, based on the Aganocide compound NVC-422, essentially act in the same manner and processes of a body's white blood cells and not as antibiotics, therefore significantly reducing the risk of a resistance being developed.
The potential of such a technology has market-moving implications, and under the circumstances, it's understandable why NBY could be tagged with an 'undervalued' label.
There are, however, a couple of reasons why investors may not yet have fully embraced the company and its technology. The first reason may be the most obvious one; that NovaBay still has nothing beyond Phase II, and therefore any investment in the company is highly speculative and risky at this point, which is a fair assessment.
That said, the best deals in biotech are the ones that are found early, when patience is needed as the trial results pan out. It's also worth noting, however, that he trend of staying away from speculative "Phase II" investments may be shifting.
Take Lpath, Inc. (LPTN), for example. Lpath also has a novel and potentially groundbreaking technology in the works, but Pfizer (PFI) has bucked the Phase II label of the company and jumped in with a very significant partnership.
CellDex Therapeutics (CLDX) is another one that has traded very highly during its Phase II stages, even when Pfizer decided to divorce itself from a partnership with the company.
In both cases, investors may have started to become clued in to how much market potential is contained within those respective pipelines and tossed the standard "wait until Phase III" strategy to the side. As investors with similar strategies in mind research NovaBay, the same potential for price appreciation exists; especially give the fact that NBY has a powerhouse partner of its own in Galderma SA, with whom NovaBay is developing a treatment for the highly-contagious skin condition, Impetigo.
Another reason why NovaBay may be missing the mark in terms of market cap right now, and this one may be more relevant than the last, is that an earlier clinical trial conducted with then-partner Alcon in the treatment of adenoviral conjunctivits - better known to the average Joe as "pink eye" - failed.
Shares slumped badly after that news hit the presses and have only barely recovered since.
On the flip side to the endpoint miss, however, which sent sent investors running for the doors, is that a further look at the data from the same trial did show that efficacy was demonstrated against Epidemic Keratoconjunctivitis (EKC), possibly the most contagious form of the infection, and which often threatens a victim's vision.
Based on that data, trials have continued, but the fact that the company has a failed trial under its belt most certainly deters some investors from jumping back in, at least until they see more results.
A Phase IIb trial for this indication is expected to begin within months, while another Phase II trial for the Impetigo condition is also slated for this year.
Results from 'Part A' from a trial testing NVC-422 as a treatment for urinary catheter blockage and encrustation (UCBE) have already rolled in, with results from 'Part B' also due within months.
The pending trial results provide some short term catalysts, but another catalyst due for this year could be the one that puts NovaBay on the map.
A commercial launch is planned for the short to mid term for NeutroPhase, NBY's first FDA-cleared product and a treatment for chronic wound in both hospital and personal care. A successful launch for NeutroPhase could alleviate many of the monetary concerns normally associated with a small company bringing its pipeline through trials, and just a couple of months ago the company announced its first strategic partner for NeutroPhase.
Having a product already on the market and bringing in revenue will go a long way to validating this small company in the eyes of potential investors, especially if the NeutroPhase commercial launch goes off without a hitch.
Based on the pending trial catalysts, the commercial launch of NeutroPhase, and most importantly, the potential of NVC-422 products on the open market as eventual substitutes for antibiotics, NBY may still be trading under the radar and could still be lightly valued, when all is considered.
By 2013 the NovaBay could have three Phase III trials ongoing with an FDA approved product on the market.
If that's the case, it's a fair bet to assume that the market cap will be significantly higher than thirty five million at that point.
For an example of how a shift from Phase II to Phase III can effect a market cap, one could look at Keryx BioPharmaceuticals (KERX). During the early to mid stages of Phase II, the KERX market cap was similar to NBY's now, but when Phase II trials were successful and Phase III came along?
Prices quickly quadrupled.
NovaBay's target market of anti-infective care is a multi-multi-billion dollar market annually, and NBY could quickly penetrate that market, as Doctors are currently looking for a way around antibiotic resistance.
As I've previously discussed, this company may be at the right place at the right time. For investors being in the right place at the right time means being "in" before any price run starts, and it's possible that NBY has a ways to move, should the pending catalysts turn out positive.
Disclosure: Long NBY.
For more information and commentary regading NBY, visit: http://vfcsstockhouse.com/blog/article/-novabay-may-be-in-the-right-place-at-the-right-time-with-an-answer-for-antibiotic-resistance
Contact VFC's Stock House: firstname.lastname@example.org
VFC's Stock House offers research-based investment information, insights and ideas on a variety of different companies in numerous sectors, with a focus on biotech stocks and healthcare.
For full reports on Celsius Holdings and other companies visit: http://vfcsstockhouse.com
Follow VFC's Stock House on Twitter: https://twitter.com/#!/VFCsStockHouse
'Like' VFC's Stock House on Facebook: http://www.facebook.com/pages/VFCs-Stock-House/143724412345213
For full disclaimer visit: http://vfcsstockhouse.com
VFC's Stock House
Health News Headlines - Yahoo News
Get the latest health news headlines from Yahoo News. Find breaking health news, including analysis and opinion on
top health stories.
Spanish judge orders release of ill boy's parents
2 Sep 2014 at 11:30am
SOTO DEL REAL, Spain (AP) ? Spanish officials have ordered the immediate release of a detained British couple who were wanted by police in the United Kingdom after they took their critically ill child for treatment abroad without doctors' consent.
Factbox: Ebola cases in the United States
21 Oct 2014 at 9:03am
(Reuters) - There have been eight cases of Ebola seen in the United States since the beginning of August. A Liberian man who died Oct. 8 in a Dallas hospital was the first person diagnosed with the virus on U.S. soil. Two hospital employees who cared for the man have been infected with the virus, which has killed more than 4,500 people and infected more than 9,100 in the worst outbreak on record, centered in three impoverished West African countries: Guinea, Sierra Leone and Liberia. ...
Nurse infected with Ebola in Spain cleared of disease
21 Oct 2014 at 8:55am
MADRID (Reuters) - A Spanish nurse infected with Ebola in Madrid while caring for a priest who later died of the virus has been cleared of the deadly disease after testing negative two times in a row, doctors said on Tuesday. "We consider her cured of the Ebola virus by World Health Organization criteria," said Jose Ramon Arribas, doctor at the Carlos III Hospital in Madrid where the nurse is being treated. ...
Tens of thousands expected to get Ebola vaccines from January: WHO
21 Oct 2014 at 8:42am
By Stephanie Nebehay GENEVA (Reuters) - Tens of thousands of people in West Africa are expected to begin getting experimental Ebola vaccines from January, but population-wide immunization is still far off, the World Health Organization (WHO) said on Tuesday. Initial clinical trials of vaccines from GlaxoSmithKline and NewLink Genetics are already under way. Some 500 volunteers are due to take part in countries including the United States, Britain, Germany, Switzerland, Mali, Gabon and Kenya. The tests will generate safety and immune-response data in December. ...
WHO: Ebola vaccine trials in W. Africa in January
21 Oct 2014 at 8:42am
GENEVA (AP) ? Tens of thousands of doses of experimental Ebola vaccines could be available for "real-world" testing in West Africa as soon as January as long as they are deemed safe, a top World Health Organization official said Tuesday.
Ebola among top U.S. worries but well behind economy, jobs: poll
21 Oct 2014 at 8:23am
(Reuters) - A new poll on Tuesday showed Ebola has moved into the top 10 issues of concern to Americans but ranks behind the economy, dissatisfaction with government and other worries. The Gallup poll was conducted before Monday's announcement that 51 people had been removed from watch lists in Texas after showing no signs of Ebola symptoms for 21 days. Scores of others are still being monitored. ...
Analysts see U.S. approval of Novo Nordisk's obesity drug by year-end
21 Oct 2014 at 7:49am
COPENHAGEN (Reuters) - The U.S. Food and Drug Administration is likely to approve Novo Nordisk's new drug to treat obesity this year, analysts said after wide expectations of an FDA decision late on Monday were not met. Danish drugmaker Novo Nordisk applied for approval for liraglutide, under the name of Saxenda, on Dec. 20 last year. Monday, exactly 10 months after the filing, was seen by analysts as a deadline for a decision from FDA about approval. FDA has set a goal to process applications for approvals within 10 months but there are examples when they spend more than that on applications. ...
Indian capital braces for worst air quality this festive week
21 Oct 2014 at 7:29am
By Aditya Kalra NEW DELHI (Reuters) - Air quality in New Delhi will deteriorate to "severe" levels this week when Indians set off firecrackers to celebrate the Hindu festival of lights, a government scientist said, leaving many at risk of respiratory problems. The warning, based for the first time on India's newly launched national Air Quality Index, is significant as New Delhi dismissed a World Health Organization study in May which found the capital to have the world's worst air pollution. ...
7 Healthy Treats to Trick Your Taste Buds This Halloween
21 Oct 2014 at 7:28am
Halloween season seems to kick off the initial downward spiral of our best eating intentions in favor of sugary confections and general holiday gluttony. It's hard not to give in to your sweet tooth when every end cap starts stocking Halloween candy come October 1, just begging us to impulse buy a modest two dozen Kit Kat bars when picking up...
Ebola galvanizes workers battling to join unions, improve safety
21 Oct 2014 at 7:09am
By Mica Rosenberg NEW YORK (Reuters) - Anthony Reynolds works on what he calls "the SWAT team of airplane cleaners," scrubbing the seats, carpets and toilets of planes parked overnight at the Philadelphia airport. About a year ago, he joined a drive to organize a union, and Ebola, he says, may help his cause. Reynolds wants more protective gear and training on how to safely handle bodily fluids, like feces and vomit, and he says that after a passenger coming down with Ebola flew on a U.S. domestic flight, concern is spreading among colleagues. ...
Ebola low among top U.S. worries, Americans warned about scams
21 Oct 2014 at 6:50am
(Reuters) - A new poll on Tuesday showed Ebola ranks well behind the economy, jobs and other issues among America's top problems, while a law enforcement official warned about Ebola-related scams promising protection against the virus that has killed thousands in West Africa. Ebola debuted in the top 10 concerns of Americans but remained far behind five other issues: the economy, dissatisfaction with government, jobs, healthcare and immigration, the Gallup polling organization said. The poll was conducted from Oct. ...
Ebola: Why virus kills some, other people survive
21 Oct 2014 at 6:43am
WASHINGTON (AP) ? People who shared an apartment with the country's first Ebola patient are emerging from quarantine healthy. And while Thomas Eric Duncan died and two U.S. nurses were infected caring for him, there are successes, too: A nurse infected in Spain has recovered, as have four American aid workers infected in West Africa. Even there, not everyone dies.
Israel's ThetaRay turns to maths to detect cyber threats
21 Oct 2014 at 6:37am
By Tova Cohen HOD HASHARON Israel (Reuters) - As businesses face a growing threat of cyber attacks, Israeli start-up ThetaRay is betting on maths to provide early detection, enabling the shutdown of systems before damage can be done. The year-old company's first investor was venture capital firm Jerusalem Venture Partners. It is now also backed by heavyweights like General Electric, which uses ThetaRay to protect critical infrastructure such as power plants, and Israel's biggest bank, Hapoalim, which deployed the technology to detect bank account anomalies. ...
Ebola Hysteria Fever: A Real Epidemic
21 Oct 2014 at 6:34am
Thus far, the Ebola virus has infected three people in the United States that we know of; however, Ebola hysteria seems to have infected somewhere close to 300 million. There are reports of kids being pulled out of schools and even some school closings. People in many areas are not going to work and others are driving cars rather than taking...
Petition calls on Roche to cut breast cancer drug price
21 Oct 2014 at 6:22am
LONDON (Reuters) - A British-led petition signed by 29,000 people has demanded that Switzerland's Roche, the world's biggest maker of cancer medicines, cut the price of its expensive new breast cancer drug Kadcyla. The campaign shows the growing pressure on drug companies as a raft of promising new cancer treatments reach the market. U.S. insurers also say they are alarmed by a coming flood of cancer medicines with "astronomical price tags", while pricing rows have flared in France and Italy. ...